Highlights

• Sun Pharma shares declined 3.87% to ₹1,650.70 during intraday trading session.
• Stock underperformed NIFTY 50 across short-term periods despite long-term gains.
• Deliverable volume stood at 49.19%, indicating relatively higher investor participation.

Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) saw its stock decline 3.87% to ₹1,650.70 on April 10, 2026, reflecting selling pressure during the session. The stock opened at ₹1,699.20 and touched an intraday high of ₹1,700.00 before falling to a low of ₹1,630.40. The volume-weighted average price (VWAP) stood at ₹1,650.53, indicating that the stock traded largely near its lower range through the day.

Trading activity remained active with 62.43 lakh shares exchanged, resulting in a traded value of ₹1,030.44 crore. Compared to the previous close of ₹1,717.10, the stock registered a notable intraday decline.

Performance Compared to Benchmark

The stock has underperformed the NIFTY 50 in the short term, reflecting a weaker trend in recent weeks. Over the past week, the stock declined 2.54% compared to a 5.80% gain in the index. On a one-month basis, the stock fell 8.95% while the index declined 0.96%.

However, the longer-term performance remains comparatively better. Over three years, the stock has gained 63.64%, outperforming the index’s 36.34% return. Over five years, it has delivered 159.21% returns against 61.98% by the benchmark. This indicates sustained long-term growth despite recent short-term weakness.

Financial Snapshot

For the quarter ended December 2025, the company reported consolidated total income of ₹16,09,938 crore, with profit before tax at ₹4,22,716 crore and net profit at ₹3,38,117 crore. Earnings per share (EPS) for the quarter stood at ₹14.00 on a consolidated basis.

On a standalone basis, total income was ₹5,86,767 crore, while net profit stood at ₹70,544 crore with an EPS of ₹2.90. These figures reflect the company’s scale of operations across domestic and global markets.

Market Indicators and Valuation Metrics

Sun Pharma’s total market capitalization stands at ₹3,96,010.24 crore, with a free float market cap of ₹1,74,308.52 crore. The stock’s deliverable quantity of 49.19% indicates a higher proportion of trades resulting in delivery, often associated with investor participation rather than speculative activity.

Other indicators include an impact cost of 0.01, suggesting high liquidity, and annualised volatility of 23.12, which is relatively moderate compared to high-beta stocks. The stock is currently trading below its 52-week high of ₹1,851.20 but remains above its 52-week low of ₹1,548.00.

Key Risks

• Short-term price decline reflects recent selling pressure in the stock.
• Underperformance versus benchmark index in recent weeks indicates weak momentum.
• Dependence on global markets exposes earnings to currency and regulatory risks.
• Moderate volatility still presents downside risk during broader market corrections.

Summary

Sun Pharma’s stock declined 3.87% to ₹1,650.70, reflecting short-term weakness amid broader market movements. The stock has underperformed the benchmark index in recent weeks but continues to show strong long-term returns over three and five years. Financial performance remains significant in scale, while liquidity indicators and moderate volatility suggest relatively stable trading conditions compared to high-beta stocks.

FAQs

1. Why did Sun Pharma stock fall today?
   The stock declined due to intraday selling pressure and weak short-term momentum compared to the broader market performance.
2. How has Sun Pharma performed over the long term?
   The stock has delivered strong returns over three and five years, outperforming the benchmark index during these periods.
3. Is Sun Pharma a volatile stock?
   The stock has moderate volatility with annualised volatility around 23.12, lower than many high-growth or speculative stocks.